{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:10:51Z","timestamp":1780416651998,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.msard.2026.106973","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:52:16Z","timestamp":1767631936000},"page":"106973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The Framingham score is a marker of early disability progression in multiple sclerosis"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4316-9389","authenticated-orcid":false,"given":"Felipe C.D.","family":"Barros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe T.L.","family":"Menezes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha P.A.","family":"Bessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa C.C.","family":"Lessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre B.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.D.","family":"Alencar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis B.","family":"Bichuetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilton A.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele S.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enedina M.L.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2026.106973_bib0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000320245","article-title":"Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study","volume":"35","author":"Christiansen","year":"2010","journal-title":"Neuroepidemiology."},{"issue":"2","key":"10.1016\/j.msard.2026.106973_bib0019","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1352458516650512","article-title":"Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course","volume":"23","author":"Conway","year":"2017","journal-title":"Mult. Scler. J."},{"issue":"6","key":"10.1016\/j.msard.2026.106973_bib0016","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care","volume":"117","author":"D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.msard.2026.106973_bib0015","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1212\/WNL.0000000000004037","article-title":"Evaluating the safety of \u03b2-interferons in MS","volume":"88","author":"de Jong","year":"2017","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.msard.2026.106973_bib0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis \u2013 a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2026.106973_bib0018","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1177\/1352458519845836","article-title":"Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis","volume":"26","author":"Fitzgerald","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.106973_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2014-310051","article-title":"Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis","author":"Kappus","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2026.106973_bib0003","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.msard.2017.08.011","article-title":"Elevated cardiovascular risk factors in multiple sclerosis","volume":"17","author":"Keytsman","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"13","key":"10.1016\/j.msard.2026.106973_bib0012","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.0b013e3181d6b125","article-title":"Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis","volume":"74","author":"Marrie","year":"2010","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.msard.2026.106973_bib0007","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/1352458514564485","article-title":"A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult. Scler. J."},{"issue":"8","key":"10.1016\/j.msard.2026.106973_bib0017","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/ene.12720","article-title":"The Framingham cardiovascular risk score in multiple sclerosis","volume":"22","author":"Moccia","year":"2015","journal-title":"Eur. J. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2026.106973_bib0010","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/jamaneurol.2020.0664","article-title":"Evaluating the risk of macrovascular events and mortality among people with multiple sclerosis in England","volume":"77","author":"Palladino","year":"2020","journal-title":"JAMa Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.106973_bib0011","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/13524585231164296","article-title":"Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: a population-based study","volume":"29","author":"Palladino","year":"2023","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2026.106973_bib0004","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/ene.14608","article-title":"The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis","volume":"28","author":"Petruzzo","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2026.106973_bib0006","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/ene.12518","article-title":"Multiple sclerosis clinical course and cardiovascular disease risk - Swedish cohort study","volume":"21","author":"Roshanisefat","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2026.106973_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104675","article-title":"Vascular disease risk factors in multiple sclerosis: effect on metabolism and brain volumes","volume":"74","author":"Sammi","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2026.106973_bib0008","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/1871527311312010016","article-title":"The prevalence of the classical and non-classical cardiovascular risk factors in multiple sclerosis patients","volume":"12","author":"Sternberg","year":"2013","journal-title":"CNS. Neurol. Disord. Drug Targets."},{"issue":"12","key":"10.1016\/j.msard.2026.106973_bib0002","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1177\/1352458510379244","article-title":"Causes of death among patients with multiple sclerosis","volume":"16","author":"Sumelahti","year":"2010","journal-title":"Mult. Scler. J."},{"issue":"6","key":"10.1016\/j.msard.2026.106973_bib0013","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1468-1331.2008.02122.x","article-title":"Smoke exposure increases the risk for multiple sclerosis","volume":"15","author":"Sundstr\u00f6m","year":"2008","journal-title":"Eur. J. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2026.106973_bib0009","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1007\/s00415-016-8295-9","article-title":"Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark","volume":"263","author":"Thormann","year":"2016","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2026.106973_bib0020","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/jnnp-2012-304740","article-title":"Lipid profiles are associated with lesion formation over 24\u2005months in interferon-\u03b2 treated patients following the first demyelinating event","volume":"84","author":"Weinstock-Guttman","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.msard.2026.106973_bib0014","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1111\/ene.15924","article-title":"UCL MS-STAT2 investigators. Cardiovascular risk factors in secondary progressive multiple sclerosis: a cross-sectional analysis from the MS-STAT2 randomized controlled trial","volume":"30","author":"Williams","year":"2023","journal-title":"Eur. J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600009X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600009X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:54:35Z","timestamp":1780415675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482600009X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":22,"alternative-id":["S221103482600009X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.106973","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Framingham score is a marker of early disability progression in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.106973","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106973"}}